Practice Point® CME Podcasts: Expert Discussions in Cardiology™

During this educational podcast, Dr. Martin Maron highlights the latest advances in HCM presented at the ESC Congress 2025 in Madrid, Spain, August 29-September 1, 2025.Noteworthy presentations, posters, and abstracts are presented from the conference that are of high clinical significance to improve HCM.Launch Date: September 2, 2025Release Date: September 2, 2025Expiration Date: August 31, 2026FACULTYMartin S. Maron, MDDirector, Hypertrophic Cardiomyopathy CenterLahey Hospital & Medical CenterMassachusetts, USAThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This is an accredited continuing education series of one (1) podcast as a downloadable audio file (MP3). This certified AMA/ABS/ANCC/ACPE podcast will spotlight latest advances in the treatment of HF featuring a leading expert reporting from the 2024 ACC Conference.Launch Date: April 11, 2024Release Date: April 11, 2024Expiration Date: March 31, 2025FACULTY BIOPeter P. Toth, MD, PhD, FCCP, FESC, FAHA, FACCDirector of Preventive CardiologyCGH Medical CenterProfessor of Clinical Family and Community MedicineUniversity of Illinois School of MedicineAdjunct Professor of MedicineDivision of CardiologyJohns Hopkins University School of MedicineThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/acc-conference-coverage-clinical-clips-in-heart-failure-1

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9). Launch Date: February 16, 2024 Release Date: January 29, 2024 Expiration Date: January 31, 2025 FACULTY R. Scott Wright, MD, FACC, FESC, FAHA Professor of Medicine Consultant in Cardiology Mayo Clinic Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI Director Mount Sinai Fuster Heart Hospital Dr. Valentin Fuster Professor of Cardiovascular Medicine Icahn School of Medicine at Mount Sinai This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).Launch Date: February 16, 2024Release Date: January 29, 2024Expiration Date: January 31, 2025FACULTYR. Scott Wright, MD, FACC, FESC, FAHAProfessor of MedicineConsultant in CardiologyMayo ClinicDeepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAIDirectorMount Sinai Fuster Heart HospitalDr. Valentin Fuster Professor of Cardiovascular MedicineIcahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).Launch Date: February 16, 2024Release Date: January 29, 2024Expiration Date: January 31, 2025FACULTYR. Scott Wright, MD, FACC, FESC, FAHAProfessor of MedicineConsultant in CardiologyMayo ClinicDeepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAIDirectorMount Sinai Fuster Heart HospitalDr. Valentin Fuster Professor of Cardiovascular MedicineIcahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link prior to listening to this episode.